• -€3.10

FLUIMUCIL MUCOL * OS 10BUST600MG

034936169
21 Items
Features:


One sachet a day.


Liquify mucus, enhanced formula.


Deductible over-the-counter drug.


Unsweetened.


Orange flavor.


















info_outline More info
Final Price 7,40
Regular Price €10.50
Save €3.10
48h
check_circle OK
Quantity

 

Convenient and safe payments

 

Shipping in 48h-72h all over the world

 

Fast returns and 14 days to reconsider

 

90 years of pharmaceutical experience at your service

Total Rating Total Rating:

0 1 2 3 4
0/5 - 0 reviews

View ratings
0 1 2 3 4 0
0 1 2 3 0 0
0 1 2 0 1 0
0 1 0 1 2 0
0 0 1 2 3 0

  Add Review View Reviews View Reviews
Pinterest


<b>15</b> Acquistando questo prodotto accumulerai 20 punti con il nostro programma fedeltà. Puoi convertire 20 punti nel tuo account in un buono per un acquisto futuro.

034936169
21 Items

FLUIMUCIL MUCOL * OS 10BUST600MG

Therapeutic indications

Treatment of respiratory diseases characterized by thick and viscous hypersecretion.

Dosage and method of use

Adults: 1 sachet of Fluimucil Mucolytic 200 mg granules for oral solution (with or without sugar) or 2 sachets of Fluimucil Mucolytic 100 mg (with or without sugar) 2-3 times a day. Fluimucil Mucolytic 200 mg, buccal tablets and effervescent tablets: 1 tablet 2-3 times a day. Fluimucil Mucolytic 100 mg / 5 ml, syrup: 10 ml of syrup (1 scoop), equal to 200 mg of N-acetylcysteine, 2-3 times a day. Fluimucil Mucolitico 600 mg / 15 ml syrup, Fluimucil Mucolitico 600 mg effervescent tablets and Fluimucil Mucolitico 600 mg granules for sugar-free solution: a 15 ml measuring spoon or an effervescent tablet or a sachet (preferably in the evening). Possible dose adjustments may relate to the frequency of administration or dose splitting but must still be within the maximum daily dose of 600 mg. Children over 2 years of age: Fluimucil Mucolytic 100 mg granules for oral solution (with or without sugar): 1 sachet 2 to 4 times a day, according to age. Fluimucil Mucolytic 100 mg / 5 ml, syrup: ½ measuring spoon of syrup (5 ml), equal to 100 mg of N-acetylcysteine, 2 to 4 times a day according to age. The duration of therapy is from 5 to 10 days. Method of administration Granules for oral solution: dissolve the contents of one sachet in a glass containing a little water, stirring as needed with a teaspoon. In this way a pleasant solution is obtained which can be drunk directly from the glass or, in the case of small children, be given in teaspoons or in a bottle. The solution should be taken as soon as it is ready. Buccal tablets: keep the tablet in the oral cavity until it is completely dissolved. Syrup: shake before using. Once opened, the syrup is valid for 15 days. Effervescent tablets: dissolve one tablet in a glass containing a little water, stirring as needed with a teaspoon. To facilitate the release of the tablet, we recommend the tear-off opening of the blister using the side notches.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Children under the age of 2. Pregnancy and breast-feeding (see section 4.6).

Side effects

Summary of the safety profile The adverse events most frequently associated with oral administration of N-acetylcysteine are gastrointestinal in nature. Hypersensitivity reactions including anaphylactic shock, anaphylactic / anaphylactoid reactions, bronchospasm, angioedema, rash and pruritus have been reported less frequently. Tabular list of adverse reactions Adverse reactions listed by classification system and frequency are presented in the following table: very common (≥ 1/10), common (≥ 1/100 to

Organ-systemic classification Adverse reactions
Uncommon (≥1 / 1,000; Rare (≥1 / 10,000; Very rare ( Not known
Disorders of the immune system Hypersensitivity Anaphylactic shock, anaphylactic / anaphylactoid reaction
Nervous system disorders Headache
Ear and labyrinth disorders Tinnitus
Cardiac pathologies Tachycardia
Vascular pathologies Hemorrhage
Respiratory, thoracic and mediastinal disorders Bronchospasm, dyspnoea Bronchial obstruction
Gastrointestinal disorders Vomiting, diarrhea, stomatitis, abdominal pain, nausea Dyspepsia
Skin and subcutaneous tissue disorders Urticaria, rash, angioedema, itching
General disorders and administration site conditions Pyrexia Edema of the face
Diagnostic tests Reduced blood pressure
Description of some adverse reactions In very rare cases, severe skin reactions have occurred in temporal connection with the intake of N-acetylcysteine, such as Stevens-Johnson syndrome and Lyell syndrome. Although in most cases at least one other suspected drug more likely involved in the genesis of the aforementioned mucocutaneous syndromes has been identified, in case of mucocutaneous alterations it is advisable to consult your doctor and the intake of N-acetylcysteine must be stopped immediately. Some studies have confirmed a reduction in platelet aggregation when taking N-acetylcysteine. The clinical significance of these findings has not yet been defined. Reporting of suspected adverse reactions Reporting of suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa.

Special warnings

Patients with bronchial asthma should be closely monitored during therapy, if bronchospasm occurs, treatment with N-acetylcysteine should be stopped immediately and appropriate treatment initiated. Mucolytics can induce bronchial obstruction in children less than 2 years of age. In fact, the drainage capacity of the bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children less than 2 years of age (see section 4.3). The use of the medicinal product in patients with peptic ulcer or with a history of peptic ulcer requires particular attention, especially in the case of concomitant use of other drugs with a known gastro-damaging effect. The possible presence of a sulphurous odor does not indicate alteration of the preparation but is typical of the active ingredient contained therein. The administration of N-acetylcysteine, especially at the beginning of the treatment, can thin the bronchial secretions and at the same time increase their volume. If the patient is unable to expectorate effectively, postural drainage and bronchoaspiration should be used to avoid secretion retention. N-acetylcysteine can affect histamine metabolism. Therefore caution should be used when administering Mucolytic Fluimucil to patients with histamine intolerance, as hypersensitivity symptoms may occur. Important information about some of the excipients The syrup contains parahydroxybenzoates which can cause delayed allergic reactions. The buccal tablets, 600 mg / 15 ml syrup and granules for oral solution without sugar contain sorbitol. Patients with hereditary fructose intolerance should not be given this medicine. The buccal tablets, effervescent tablets and granules for oral solution without sugar contain aspartame, a source of phenylalanine which may be harmful in patients with phenylketonuria. The 100 mg and 200 mg granules for oral solution contain sunset yellow (E110) which can cause allergic reactions. The 100 and 200 mg granules for oral solution contain sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicinal product. The 200 mg granules for oral solution contains 2.2 g of sucrose per sachet while the 100 mg granules for oral solution contains 4.3 g of sucrose per sachet so it should be taken into consideration in patients with diabetes mellitus. The buccal tablets contain 26.9 mg of sodium per dose, equivalent to 1.3% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The effervescent tablets contain 156.9 mg of sodium per dose, equivalent to 7.8% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The 100 mg / 5 ml (150 ml) syrup contains 37.5 mg of sodium per 10 ml dose, equivalent to 1.8% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The 100 mg / 5 ml (150 ml) syrup contains 18.8 mg of sodium per 5 ml dose, equivalent to 0.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The 100 mg / 5 ml (200 ml) syrup contains 38.2 mg of sodium per 10 ml dose, equivalent to 1.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The 100 mg / 5 ml (200 ml) syrup contains 19.1 mg of sodium for the 5 ml dose, equivalent to 0.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The 600 mg / 15 ml syrup contains 96.6 mg of sodium for the 15 ml dose, equivalent to 4.8% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult.

Pregnancy and breastfeeding

Even if the teratological studies conducted with Fluimucil Mucolytic on animals did not show any teratogenic effect, however, as for other drugs, its administration during pregnancy and during the period of breastfeeding with breast milk, should be carried out only in case of real need .

Expiration and retention

Sachets of 100 and 200 granules for oral solution, 600 mg granules for oral solution without sugar, 200 mg granules for oral solution without sugar and 200 mg buccal tablets: store at a temperature not exceeding 30 ° C.

Interactions with other drugs

Drug-drug interaction. Antitussive drugs and mucolytic agents, such as N-acetylcysteine, should not be taken at the same time as the reduced cough reflex could lead to an accumulation of bronchial secretions. Activated carbon can reduce the effect of N-acetylcysteine. It is advisable not to mix other drugs with Fluimucil Mucolytic solution. The information available on the antibiotic-N-acetylcysteine interaction refers to in vitro tests, in which the two substances were mixed, which showed a decreased activity of the antibiotic. However, as a precaution, it is recommended to take antibiotics by mouth at least two hours after the administration of N-acetylcysteine, with the exception of loracarbef. It has been shown that the simultaneous intake of nitroglycerin and N-acetylcysteine causes significant hypotension and causes dilation of the temporal artery with possible onset of headache. If the simultaneous administration of nitroglycerin and N-acetylcysteine is necessary, patients should be monitored for the onset of hypotension, which can also be severe, and warned about the possible onset of headache. Pediatric population Interaction studies have only been performed in adults. Drug-laboratory test interactions N-acetylcysteine can cause interference with the colorimetric assay method for the determination of salicylates. N-acetylcysteine can interfere with the test for the determination of ketones in urine.

Overdose

No cases of overdose have been reported with respect to oral administration of N-acetylcysteine. Healthy volunteers who took a daily dose of N-acetylcysteine of 11.6 g for three months did not show any serious adverse reactions. Doses up to 500 mg NAC / kg body weight, administered orally, were tolerated without any symptoms of intoxication. Symptoms Overdose can cause gastrointestinal symptoms such as nausea, vomiting and diarrhea. Treatment There are no specific antidotic treatments; overdose therapy is based on symptomatic treatment.

Active principles

FLUIMUCIL MUCOLITICO 600 mg effervescent tablets Each tablet contains: Active ingredient N-acetylcysteine 600 mg Excipients with known effects: sodium, aspartame FLUIMUCIL MUCOLITICO 600 mg granules for oral solution without sugar Each sachet contains: Active ingredient N-acetylcysteine 600 mg Excipients with known effects: aspartame, sorbitol FLUIMUCIL MUCOLITICO 600 mg / 15 ml syrup 15 ml of syrup contain: Active ingredient N-acetylcysteine mg 600 Excipients with known effects: methyl para-hydroxybenzoate, propyl para-hydroxybenzoate, sodium, sorbitol FLUIMUCIL MUCOLITICO 200 mg, effervescent tablets: One tablet contains: Active ingredient N-acetylcysteine mg 200 Excipients with known effects: sodium, aspartame FLUIMUCIL MUCOLITICO 200 mg, buccal tablets: One tablet contains: Active principle N-acetylcysteine mg 200 Excipients with known effects: sorbitol, sodium, aspartame FLUIMUCIL MUCOLITICO 200 mg, granules for oral solution One sachet contains: Active principle N-acetylcysteine mg 200 Excipients with known effects: sucrose, sunset yellow (E110) FLUIMUCIL MUCOLITICO 200 mg, granules for oral solution without sugar One sachet contains: Active principle N-acetylcysteine mg 200 Excipients with known effects: sorbitol, aspartame FLUIMUCIL MUCOLITICO 100 mg, granules for oral solution One sachet contains: Active principle N-acetylcysteine mg 100 Excipients with known effects: sucrose, sunset yellow (E110) FLUIMUCIL MUCOLITICO 100 mg, granules for oral solution without sugar One sachet contains: Active principle N-acetylcysteine mg 100 Excipients with known effects: sorbitol, aspartame FLUIMUCIL MUCOLITICO 100 mg / 5 ml, syrup A 150ml bottle contains: Active principle N-acetylcysteine g 3,000 (corresponding to 100 mg / 5 ml of syrup) Excipients with known effects: methyl parahydroxybenzoate, sodium One bottle of 200 ml contains: Active principle 4,000 g N-acetylcysteine (corresponding to 100 mg / 5 ml syrup) Excipients with known effect: methyl parahydroxybenzoate, sodium For a full list of excipients, see section 6.1

Excipients

FLUIMUCIL MUCOLITICO 600 mg granules for oral solution without sugar Aspartame, Orange flavor, Sorbitol. FLUIMUCIL MUCOLITICO 600 mg effervescent tablets Anhydrous citric acid, Lemon flavor, Aspartame, Sodium bicarbonate. FLUIMUCIL MUCOLITICO 600 mg / 15 ml syrup 200 ml bottleMethyl parahydroxybenzoate, Propyl parahydroxybenzoate, Sodium edetate, Carmellose, Saccharin sodium, Grenadine flavor, Strawberry flavor, Sorbitol, Sodium hydroxide, Purified water. FLUIMUCIL MUCOLITICO 200 mg including orosoluble Anhydrous citric acid, sorbitol, mannitol, polyethylene glycol 6000, povidone, sodium bicarbonate, lemon flavor, mandarin flavor, aspartame, magnesium stearate, microcrystalline cellulose. FLUIMUCIL MUCOLITICO 200 mg granules for oral solution without sugar Sorbitol, aspartame, orange flavor. FLUIMUCIL MUCOLITICO 200 mg granules for oral solutionOrange juice granules; Orange flavor; Saccharin; E 110; Sucrose. FLUIMUCIL MUCOLITICO 200 mg including effervescent Anhydrous citric acid, sodium bicarbonate, lemon flavor, aspartame. FLUIMUCIL MUCOLITICO 100 mg granules for oral solutionOrange juice granules; Orange flavor; Saccharin; E 110; Sucrose. FLUIMUCIL MUCOLITICO 100 mg granules for oral solution without sugar Sorbitol; Aspartame; Orange flavor. FLUIMUCIL MUCOLITICO 100 mg / 5 ml syrup 150 ml bottle Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethylcellulose, raspberry flavor, sodium saccharinate, sodium hydroxide, purified water. FLUIMUCIL MUCOLITICO 100 mg / 5 ml syrup 200 ml bottle Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethylcellulose, sodium cyclamate, sucralose, raspberry flavor, sodium saccharinate, sodium hydroxide, purified water.

034936169
21 Items

Payment Methods

Delivery Methods

chat Comments (0)

Reviews Reviews (0)

Based on 0 reviews - 0 1 2 3 4 0/5